Geoffrey Wing-Lynn Chan, MD

faculty photo
Adjunct Assistant Professor of Medicine
Department: Medicine

Contact information
1250 S Collegeville Rd, UP4315
Collegeville, PA 19426
Office: 610-917-5256
Fax: 617-917-6119
Education:
BA (Economics)
Boston College, 1992.
MD (Internal Medicine)
Brown University School of Medicine, 1996.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK16, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK.: Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 386(1004): 1649-58, Oct 24 2015.

Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB, Matthews DC, Lambert MP, Marcello LM, Iyengar M, Chan GW, Chagin KD, Theodore D, Bailey CK, Bakshi KK.: Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2(8): e315-25, Aug 2015.

Moshe Mittelman, Sarit Assouline, Evangelos Briasoulis, Arancha Alonso, Regina Garcia Delgada, Peter O’Gorman, Hyeoung Joon Kim, Sung-Soo Yoon, Andre Zaritskey, Catherine Flynn, Yoo-Hong Min, Maria-Diez-Campelo, Alexandr Myasnikov, Frank Mannino, Yasser Mostafa Kamel, Conrad Messam, Nicole L. Stone, and Geoffrey W. Chan: Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study. Blood (ASH Annual Meeting Abstracts) 633(3822), Nov 2012.

Wierda, WG, Jewell, RC, Kipps, TJ, Durig, J, Griskevicius, L, Stilgenbauer, S, Smolej, L, Hess, G, Hernandez-Ilizaliturri, FJ, Padmanabhan, S, Fang, L, Gorczyca, MM, Chan, GW, Gupta, IV, Lisby, S: Correlations Between Ofatumumab Exposure and Treatment Outcomes for patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy. Blood 118(21): 782-783, NOV 18 2011.

Wierda, WG, Padmanabhan, S, Chan, GW, Gupta, IV, Lisby, S, Osterborg, A: Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 118(19): 5126-5129, NOV 10 2011.

Poutsiaka, DD, Munson, D, Price, LL, Chan, GW, Snydman, DR: Blood stream infection (BSI) and acute GVHD after hematopoietic SCT (HSCT) are associated. Bone Marrow Transplantation 46(2): 300-307, FEB 2011.

William G. Wierda, Thomas J. Kipps, Jan Du¨rig, Laimonas Griskevicius, Stephan Stilgenbauer, Jirˇí Mayer, Luka´sˇ Smolej, Georg Hess, Rasa Griniute, Francisco J. Hernandez-Ilizaliturri, Swaminathan Padmanabhan, Michele Gorczyca, Chai-Ni Chang, Geoffrey Chan, Ira Gupta, Tina G. Nielsen, and Charlotte A. Russell on behalf of the 407 Study Investigators: Chemoimmunotherapy with OF-C in Previously Untreated Patients with Chronic Lymphocytic Leukemia. Blood 117(24): 6450-6458, 2011.

Wierda, WG, Kipps, TJ, Mayer, J, Robak, T, Dyer, MJS, Eurman, RR, Hillmen, P, Stilgenbauer, S, Williams, CD, Trneny, M, Cartron, G, Hernandez-Ilizaliturri, FJ, Padmanabhan, S, Chan, GW, Gupta, IV, Gorczyca, MM, Davis, RL, Losic, N, Lisby, S, Osterborg, A: Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. Blood 116(21): 406-407, NOV 19 2010.

William G. Wierda, Thomas J. Kipps, Jirˇí Mayer, Stephan Stilgenbauer, Cathy D. Williams, Andrzej Hellmann, Tadeusz Robak, Richard R. Furman, Peter Hillmen, Marek Trneny, Martin J.S. Dyer, Swami Padmanabhan, Magdalena Piotrowska, Tomas Kozak, Geoffrey Chan, Randy Davis, Nedjad Losic, Joris Wilms, Charlotte A. Russell, and Anders Österborg: Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology(28), 1749-55, 2010.

William G Wierda, Thomas J Kipps, Jan Durig, Laimonas Griskevicius, Stephan Stilgenbauer, Jiri Mayer, Lukas Smolej, Georg Hess, Rasa Griniute, Francisco J Hernandez-Ilizaliturri, Swaminathan Padmanabhan, Michele Gorczyca, Geoffrey Chan, Ira Gupta, Marc Andersen, Claus Strange, Tina G Nielsen, and Charlotte A Russell: Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial. Blood (ASH Annual Meeting Abstracts) 112(207), Nov 2009.

back to top
Last updated: 12/04/2017
The Trustees of the University of Pennsylvania